.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Harvard Business School
Fuji
Chinese Patent Office
Accenture
Teva
Covington
Mallinckrodt
Boehringer Ingelheim
Dow

Generated: July 23, 2017

DrugPatentWatch Database Preview

Schering Company Profile

« Back to Dashboard

What is the competitive landscape for SCHERING, and what generic alternatives to SCHERING drugs are available?

SCHERING has one hundred and two approved drugs.

There are nine US patents protecting SCHERING drugs on SCHERING drugs in the past three years.

There are eighty-three patent family members on SCHERING drugs in thirty-two countries.

Summary for Applicant: Schering

Patents:9
Tradenames:64
Ingredients:56
NDAs:102
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
NORMODYNE
labetalol hydrochloride
TABLET;ORAL018687-003Aug 1, 1984DISCNYesNo► Subscribe► Subscribe
Schering
PROPRANOLOL HYDROCHLORIDE
propranolol hydrochloride
TABLET;ORAL070120-001Aug 6, 1985DISCNNoNo► Subscribe► Subscribe
Schering
NORMODYNE
labetalol hydrochloride
INJECTABLE;INJECTION018686-001Aug 1, 1984DISCNNoNo► Subscribe► Subscribe
Schering
THEOVENT
theophylline
CAPSULE, EXTENDED RELEASE;ORAL087010-001Jan 31, 1985DISCNNoNo► Subscribe► Subscribe
Schering
TINDAL
acetophenazine maleate
TABLET;ORAL012254-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Schering

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering
LOTRIMIN
clotrimazole
LOTION;TOPICAL018813-001Feb 17, 19843,705,172► Subscribe
Schering
RENORMAX
spirapril hydrochloride
TABLET;ORAL020240-002Dec 29, 19944,470,972► Subscribe
Schering
INTEGRILIN
eptifibatide
INJECTABLE;INJECTION020718-001May 18, 19985,756,451► Subscribe
Schering
REBETOL
ribavirin
SOLUTION;ORAL021546-001Jul 29, 20036,063,772*PED► Subscribe
Schering
VANCENASE
beclomethasone dipropionate
AEROSOL, METERED;NASAL018521-001Approved Prior to Jan 1, 19824,414,209► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SCHERING drugs

Drugname Dosage Strength Tradename Submissiondate
posaconazole
Injection18 mg/mL, 16.7 mL vials
NOXAFIL
11/24/2015
posaconazole
Delayed-release Tablets100 mg
NOXAFIL
6/16/2014
posaconazole
Oral Suspension40 mg/mL
NOXAFIL
2/28/2011
eptifibatide
Injection0.75 mg/mL, 100 mL vial
INTEGRILIN
6/5/2009
eptifibatide
Injection2 mg/mL, 100 mL vial
INTEGRILIN
12/18/2008
eptifibatide
Injection2 mg/mL, 10 mL vial
INTEGRILIN
9/30/2008

Non-Orange Book Patents for Schering

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,714,490 Tetrahydrofuran antifungals► Subscribe
6,713,481 Crystalline antifungal polymorph► Subscribe
5,693,626 Tetrahydrofuran antifungals► Subscribe
5,703,236 Tetrahydrofuran antifungals► Subscribe
5,710,154 Tetrahydrofuran antifungals► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Schering Drugs

Country Document Number Estimated Expiration
Canada2179396► Subscribe
Denmark0736030► Subscribe
China1499930► Subscribe
Japan4308902► Subscribe
European Patent Office1372394► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Schering Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
323Luxembourg► SubscribePRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Julphar
Accenture
UBS
Cerilliant
Farmers Insurance
Daiichi Sankyo
AstraZeneca
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot